← All trials
NCT05659147
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2027
- First posted
- Dec 21, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 195
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CincinnatiLead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of CincinnatiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.